Common questions about our model, how we work with companies, and what makes us different.
Learn MoreFrom Pre-IND to NDA and everything in between, RRD has a proven track record of successful client engagements.
Learn More
Executive Bios
- Charles (Chuck) Finn
- Frank Hurley
- Carolyn Pratt
- J. Scott Tarrant
- Curt Scribner
- Robert Smith
- Marc Alderdice
- Patrick (Pat) Frenchick
- Maryann Krane
Charles (Chuck) Finn, PhD, President and Chief Executive Officer, Co-Founder
Dr. Finn is President and Chief Executive Officer at RRD International, LLC. Dr. Finn is responsible for the overall direction of RRD and the management of RRD’s core development teams. Dr. Finn has more than 20 years of experience in the research, development, and government regulation of biological and pharmaceutical products covering a wide range of product types and therapeutic indications. Dr. Finn began his career as a Staff Fellow at FDA, Center for Biologics Evaluation and Research. He then entered industry, where he has held senior positions of increasing responsibility in regulatory affairs and product development. Dr. Finn worked for several companies prior to co-founding RRD, including Lederle-Praxis Biologicals, Miles Pharmaceuticals, Genetics Institute, BRI International, Quintiles, and Prestwick Clinical. Dr. Finn has extensive experience in establishing and managing drug development project teams. Dr. Finn received a PhD in Biology from Georgetown University and a BS in Zoology from the University of Maryland.
Frank Hurley, PhD, Chief Scientific Officer, Co-Founder
Dr. Hurley is Chief Scientific Officer at RRD International, LLC. Dr. Hurley has more than 30 years of experience in assisting companies with their regulatory, research, and product development strategies. His expertise includes clinical trial design and analysis, review of preclinical and clinical information, preparation of regulatory documents, and presentations to government regulatory agencies. Dr. Hurley is a recognized published educator and authority on research strategy and study design for pharmaceuticals, biologics, and medical devices. Dr. Hurley co-founded BRI International, Inc. in 1971 and guided its growth as both Chairman and Chief Scientific Officer until he merged BRI with Quintiles Transnational, Inc. in 1996. Dr. Hurley served as Chief Scientific Officer of Quintiles until 2001. Dr. Hurley received a PhD in Biostatistics from Johns Hopkins University and a BS in Mathematics and Pre-Medical Sciences from Georgetown University.
Carolyn Pratt, Executive Vice President
Ms. Pratt is Executive Vice President of RRD International, LLC. Ms. Pratt joined RRD after spending five years in investment banking, most recently with Needham & Co., where she was Senior Analyst covering the biotech sector, and, prior to that, at Montgomery Securities. Ms. Pratt was at Genetics Institute for seven years, where she worked as Manager of Business Development and as Product Manager for a novel protein therapeutic. She began her professional career with the Ortho Pharmaceuticals division of Johnson & Johnson, where she worked in clinical research and also in sales and participated in the development and commercial launch of the first FDA-approved therapeutic monoclonal antibody. Ms. Pratt holds a degree in Pharmacy.
J. Scott Tarrant, Chief Business Officer
Mr. Tarrant has over 20 years of technical sales, marketing and business development experience with companies ranging from early stage start-ups to large publically traded entities. As Partner and Co-Founder of Catenate, LLC he has worked closely with a number of early stage life science companies developing and supporting their corporate and business strategies. Mr. Tarrant served previously as EVP Global Sales and Marketing for UK based Xceleron Ltd, joining the company in 2004, and leading the formation of Xceleron’s US subsidiary in Maryland. Mr. Tarrant has also held executive and sales management positions at Gene Logic, TherImmune Research Corporation and Nalco Chemical Company. Mr. Tarrant is a former combat engineer officer in the United States Army. He received his B.S. in Biology from SUNY College of Environmental Science and Syracuse University and is a 2008 graduate of the International Executive Program in General Management at INSEAD, Fontainebleau, France and Singapore.
Curt Scribner, MD, MBA, Senior Vice President of Medical and Regulatory Affairs
Dr. Scribner is Senior Vice President of Medical and Regulatory Affairs at RRD International, LLC. Dr. Scribner is a board certified physician in internal medicine and has direct experience running large clinical programs. He joined RRD from Intarcia Therapeutics, where he was the Vice President of Regulatory and Quality Affairs and Chief Regulatory Officer. Previously, Dr. Scribner was Chief Regulatory Consultant for Quintiles Consulting, where he developed and wrote numerous NDA, BLA, IND, IDE, 510(k), PMA, and MAA applications. Prior to Quintiles Consulting, Dr. Scribner spent 10 years at FDA, where he held a variety of positions and was involved in reviewing products regulated by the Center for Biologics. Dr. Scribner holds an MD from the University of Colorado College of Medicine, an MBA from the University of Maryland College of Business and Management, and a BA in biology from Grinnell College.
Robert L Smith, Jr., CPA, Senior Vice President of Finance and Administration
Mr. Smith is Senior Vice President, Finance and Administration, at RRD International, LLC. Mr. Smith is a CPA and has extensive experience in the areas of financial reporting, accounting systems, auditing, budgeting and analysis, cost control, and financial management. Previous employers have consisted predominately of small (including start-up) to mid-size firms providing products and services to the biotechnology, pharmaceutical, and medical research industries. He is recognized for his ability to successfully organize, plan, and coordinate staff efforts in start-up ventures, finance system conversions, systems integrations, and mergers/acquisitions. Mr. Smith was previously Vice President of Finance and Administration for East West Resources Corporation, a private investment management firm. Prior to that he was Divisional Vice President of Finance at Quintiles Transnational Corp. Mr. Smith began his career as a Senior Staff Accountant at Arthur Andersen & Company in Baltimore, MD.
Marc Alderdice, PhD, Vice President of Operations and Senior Program Leader
Dr. Alderdice is Vice President of Operations and Senior Program Leader at RRD International, LLC. Dr. Alderdice is responsible for the oversight of all RRD projects. Dr. Alderdice has more than 30 years of experience in program management and in the planning and implementation of multi-national clinical trials. Prior to RRD he held the titles of Sr. Product Director and Director of Project Management at PRA International, and before that he held positions at Quintiles/BRI, Sigma-Tau Pharmaceuticals, and Bristol Myers Squibb. Dr. Alderdice received a PhD in Pharmacology from the University of Texas Health Science Center, completed his Postdoctoral Fellowship at the University of Connecticut, and then was Assistant Professor of Pharmacology and Experimental Therapeutics at the LSU Medical Center in New Orleans.
Patrick (Pat) Frenchick, PhD, MBA, Vice President of Scientific and Technical Operations
Dr. Frenchick has over 20 years of experience in the development of new technologies and moving these into early clinical trials. Prior to joining RRD, he was Vice President for Clinical Operations at CytImmune Sciences, and before that Vice President of Development at Combinature BioPharma. He has worked in senior positions in the acquisition of technologies, strategic planning, and portfolio management in the US and in Europe. Dr. Frenchick received his PhD in Immunology from the University of Minnesota, an MBA from Queen’s University (Kingston, ON, Canada), and is a US Patent Agent. He was a Postdoctoral Fellow in Virology at Baylor College of Medicine and a Research Faculty member at the Veterinary Infectious Disease Organization and Adjunct Assistant Professor of Microbiology at the University of Saskatchewan.
Maryann Krane, Senior Technical Advisor
Maryann Krane is a Senior Technical Advisor of RRD International, LLC. Ms. Krane joined RRD from Ariad Pharmaceuticals, Inc. where she was Vice President of Regulatory Affairs and Corporate Quality. Previously, Ms. Krane held management level positions at several biotechnology companies, including Genetics Institute and Wyeth Pharmaceuticals. Ms. Krane has broad drug development experience in multiple therapeutic areas including hematology/oncology, neurology, endocrinology, pulmonary and special pathogens. She has developed successful global product registration strategies for several hematology and oncology products and has extensive submission experience developing IND, BLA, MAA, NDS, Orphan Designation, Fast Track, Special Protocol Assistance and European Scientific Advice applications. Ms. Krane holds a BS in Microbiology from the University of Massachusetts.